| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

证券代码：002940 证券简称：昂利康 公告编号：2025-106 浙江昂利康制药股份有限公司 关于募集资金投资项目之杭州药物研发平台项目延期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召 开第四届董事会第十六次会议，审议通过了《关于募集资金投资项目之杭州药物 研发平台项目延期的议案》，同意公司在募投项目实施主体、募集资金投资用途 及规模不发生变更的情况下，将 2020 年非公开发行股票的"杭州药物研发平台" 项目达到预定可使用状态的日期由 2025 年 12 月延期至 2026 年 6 月。本次募投项 目延期事项在董事会审批权限范围内，无需提交股东会审议。现将有关情况公告 如下： 一、2020 年非公开发行股票募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准浙江昂利康制药股份有限公司非公开 发行股票的批复》（证监许可〔2020〕2271 号）核准，并经深圳证券交易所同意， 本公司由主承销商东方证券股份有限公司（以下简称"东 ...

东方证券股份有限公司 关于浙江昂利康制药股份有限公司 募集资金投资项目之杭州药物研发平台项目延期的 核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为浙江 昂利康制药股份有限公司（以下简称"昂利康"或"公司"）2020 年非公开发行 的保荐机构，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》《上市公司募集资金监管规则》 和公司《募集资金管理制度》等有关文件的要求，对公司将募集资金投资项目之 "杭州药物研发平台"项目延期的事项进行了认真、审慎的核查，具体情况如下： 一、2020 年非公开发行股票募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准浙江昂利康制药股份有限公司非公开 发行股票的批复》（证监许可〔2020〕2271 号）核准，并经深圳证券交易所同意， 公司由主承销商东方证券采用询价方式，向特定投资者非公开发行人民币普通股 （A 股）股票 594.68 万股，发行价格为每股人民币 46.26 元，共计募集资金总额 为人民币 27,509.98 万元坐扣承销和保荐费用 550 万元后的 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江昂利康制药股份有限公司（以下简称"公司"）第四届董事会第十六次 会议（以下简称"会议"）通知于 2025 年 12 月 29 日以专人送达、邮件等方式 发出，会议于 2025 年 12 月 30 日以通讯方式召开。本次会议的应表决董事 7 人， 实际参与表决董事 7 人，会议由董事长方南平先生主持。会议的通知、召开以及 参与表决董事人数均符合相关法律、法规、规则及《浙江昂利康制药股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于豁免本次董事会通知期限的议案》 表决结果：7 票同意，0 票反对，0 票弃权 证券代码：002940 证券简称：昂利康 公告编号：2025-105 浙江昂利康制药股份有限公司 关于第四届董事会第十六次会议决议的公告 具体内容详见 2025 年 12 月 31 日公司在《证券时报》及巨潮资讯网 （www.cninfo.com.cn）上刊载的《关于募集资金投资项目之杭州药物研发平台项 目延期的 ...

Group 1 - The clinical trial for Amoxicillin capsules by Zhejiang Anglikang Pharmaceutical Co., Ltd. has been initiated, focusing on the bioequivalence study in healthy Chinese subjects [1] - The trial is designed as a single-center, open-label, randomized, single-dose, two-period, two-sequence, and crossover study, with a clinical trial registration number of CTR20255192 [1] - The primary objective is to evaluate the pharmacokinetics of the test formulation compared to the reference formulation under fasting conditions, while the secondary objective assesses the safety of both formulations [1] Group 2 - The trial's primary endpoints include Cmax, AUC0-t, AUC0-∞, vital signs, physical examinations, 12-lead ECG, clinical laboratory tests, and adverse events, evaluated 12 hours post-administration [2] - Secondary endpoints consist of Tmax, t1/2, λz, AUC_%Extrap, Vd/F, CL/F, F, along with the same safety assessments as primary endpoints, evaluated until the end of follow-up [2] - The current status of the trial is ongoing, with a target enrollment of 24 participants [3]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002940 证券简称：昂利康 公告编号：2025-103 浙江昂利康制药股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示 1、为尊重中小投资者利益，提高中小投资者对公司股东会审议的重大事项参与度，本次股东会审议的 部分议案对中小投资者实行单独计票。中小投资者是指除以下股东以外的其他股东：（1）上市公司的 董事、高级管理人员；（2）单独或者合计持有上市公司5%以上股份的股东； 2、本次股东会无否决或修改议案情况； 3、本次股东会没有涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025年12月16日下午14：00 网络投票时间：2025年12月16日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为2025年12月16日上午9：15 至 9：25， 9：30至11：30和下午13：00至15：00； 通过深圳证券交易所互联网投票系统（http://wltp.cninfo ...

昂利康公告称，因与关联方白云山昂利康经营活动需要，拟增加关联交易预计额度。原预计2025年向其 采购电金额由38万元增至45万元，不调整子公司动保科技采购额度，原预计与其他关联方交易及金额不 变。调整后，2025年度日常关联交易预计发生额不超1655万元（不含税）。本次增加金额未达公司最近 一期经审计净资产的0.5%，属总经理决策权限，无需董事会和股东会审议，不构成重大资产重组。 ...

证券代码：002940 证券简称：昂利康 公告编号：2025-104 浙江昂利康制药股份有限公司 关于增加 2025 年度日常关联交易预计额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"或"昂利康"）于 2025 年 12 月 16 日召开经营管理层会议，同意公司增加 2025 年度日常关联交易预计 额度，现将具体情况公告如下： 一、日常关联交易基本情况 现由于公司与关联方浙江白云山昂利康制药股份有限公司（以下简称"白云 山昂利康"）经营活动需要，拟增加关联交易预计额度。公司原预计 2025 年公司 子公司浙江昂利康动保科技有限公司（以下简称"动保科技"）向白云山昂利康 采购商品即采购电的预计金额为 36 万元（不含税），公司向白云山昂利康采购商 品即采购电的关联交易预计金额为 2 万元（不含税），现根据实际经营情况，拟 增加关联交易预计额度。公司拟增加向白云山昂利康采购商品的关联交易预计额 度，即原预计公司 2025 年向白云山昂利康采购商品即采购电的金额由 2 万元增 1 加至 9 万元，不调整动保科 ...